Blab Tech
Canadian MedTech Startup Reveal Life Science Wins Top Prize at Paris VivaTech
Montreal‑based medical AI company Reveal Life Science secured first place in the OVHcloud Startup Challenge at VivaTech in Paris on Thursday, outperforming dozens of international competitors. The award recognizes the company’s platform that uses Raman spectroscopy to analyze tissue samples in seconds, determining whether they are healthy or cancerous. Reveal claims its artificial‑intelligence system is supported by the world’s largest collection of molecular data.
Reveal’s technology relies on Raman spectroscopy, a spectroscopic technique that measures vibrational modes of molecules. The method uses a monochromatic laser source to illuminate a sample; scattered photons are collected and dispersed onto a detector. The energy shift of the scattered light provides a chemical fingerprint that can identify tissue composition. Because the technique is non‑destructive and rapid, it can be applied during surgery to give surgeons real‑time feedback on tumor margins.
Raman spectroscopy has been used in research for decades, but its adoption in clinical settings has been limited by instrument cost and data analysis complexity. Reveal’s platform addresses these barriers by embedding machine‑learning algorithms that automatically interpret spectra and provide a binary classification of tissue status within seconds. The company’s claim that its dataset is the largest in the world is supported by the 20,000 intraoperative measurements it has collected, which feed the AI model and improve its predictive accuracy over time.
The company’s platform is built on data infrastructure provided by fellow Canadian firm Qohash. Qohash CEO Jean Le Bouthillier said in a statement that “control of sensitive data is a strategic advantage” and that the company “ensures that the most critical medical data never leaves the control of those who hold it.” The partnership allows Reveal to host and process its large datasets while maintaining strict data sovereignty.
Reveal’s stated goal is to eliminate residual cancerous tissue during operations, thereby reducing the risk of recurrence. The company reports that its system has been validated in more than 700 surgeries and 20,000 intraoperative measurements. Accuracy figures for brain‑tumor detection range from 93 % to 97 %, according to the company. While the platform has not yet achieved a margin‑of‑error free outcome, the performance metrics are among the highest reported for intraoperative tissue assessment.
In addition to the VivaTech award, Reveal has obtained an FDA Breakthrough Device designation, a status that can accelerate regulatory review in the United States. The designation does not mean the device is cleared for sale; the company remains in the process of obtaining full clearance.
This month, Reveal announced a Canada‑France partnership with the surgical innovation centre IRCAD to bring its AI system to breast‑cancer surgery. The collaboration aims to integrate the platform into clinical workflows, but the device has not yet been cleared for commercial use.
The award ceremony was part of the OVHcloud Startup Challenge, a competition hosted by French cloud provider OVHcloud that highlights emerging technology companies. Reveal’s victory comes amid a broader Canadian presence at VivaTech, led by federal AI supercluster Scale AI, which is showcasing Canadian AI talent to international investors and partners.
The event underscores the growing interest in AI‑driven surgical tools and the importance of data infrastructure that protects patient privacy. Reveal’s approach, combining Raman spectroscopy with large‑scale molecular datasets, represents a significant step toward more precise, real‑time decision support in operating rooms.
At present, Reveal continues to refine its algorithms and expand clinical validation. The company is awaiting final regulatory clearance in the United States and is working to establish commercial distribution channels. The Canada‑France partnership with IRCAD is expected to advance the platform’s readiness for breast‑cancer surgery, while the VivaTech award raises the company’s profile among global investors and potential collaborators.
Reveal’s technology relies on Raman spectroscopy, a spectroscopic technique that measures vibrational modes of molecules. The method uses a monochromatic laser source to illuminate a sample; scattered photons are collected and dispersed onto a detector. The energy shift of the scattered light provides a chemical fingerprint that can identify tissue composition. Because the technique is non‑destructive and rapid, it can be applied during surgery to give surgeons real‑time feedback on tumor margins.
Raman spectroscopy has been used in research for decades, but its adoption in clinical settings has been limited by instrument cost and data analysis complexity. Reveal’s platform addresses these barriers by embedding machine‑learning algorithms that automatically interpret spectra and provide a binary classification of tissue status within seconds. The company’s claim that its dataset is the largest in the world is supported by the 20,000 intraoperative measurements it has collected, which feed the AI model and improve its predictive accuracy over time.
The company’s platform is built on data infrastructure provided by fellow Canadian firm Qohash. Qohash CEO Jean Le Bouthillier said in a statement that “control of sensitive data is a strategic advantage” and that the company “ensures that the most critical medical data never leaves the control of those who hold it.” The partnership allows Reveal to host and process its large datasets while maintaining strict data sovereignty.
Reveal’s stated goal is to eliminate residual cancerous tissue during operations, thereby reducing the risk of recurrence. The company reports that its system has been validated in more than 700 surgeries and 20,000 intraoperative measurements. Accuracy figures for brain‑tumor detection range from 93 % to 97 %, according to the company. While the platform has not yet achieved a margin‑of‑error free outcome, the performance metrics are among the highest reported for intraoperative tissue assessment.
In addition to the VivaTech award, Reveal has obtained an FDA Breakthrough Device designation, a status that can accelerate regulatory review in the United States. The designation does not mean the device is cleared for sale; the company remains in the process of obtaining full clearance.
This month, Reveal announced a Canada‑France partnership with the surgical innovation centre IRCAD to bring its AI system to breast‑cancer surgery. The collaboration aims to integrate the platform into clinical workflows, but the device has not yet been cleared for commercial use.
The award ceremony was part of the OVHcloud Startup Challenge, a competition hosted by French cloud provider OVHcloud that highlights emerging technology companies. Reveal’s victory comes amid a broader Canadian presence at VivaTech, led by federal AI supercluster Scale AI, which is showcasing Canadian AI talent to international investors and partners.
The event underscores the growing interest in AI‑driven surgical tools and the importance of data infrastructure that protects patient privacy. Reveal’s approach, combining Raman spectroscopy with large‑scale molecular datasets, represents a significant step toward more precise, real‑time decision support in operating rooms.
At present, Reveal continues to refine its algorithms and expand clinical validation. The company is awaiting final regulatory clearance in the United States and is working to establish commercial distribution channels. The Canada‑France partnership with IRCAD is expected to advance the platform’s readiness for breast‑cancer surgery, while the VivaTech award raises the company’s profile among global investors and potential collaborators.
